Natera stock analysis
Want to see NTRA full AI Analyst Report?
Natera (NTRA) Stock Price & Analysis
NTRA Stock Chart & Stats
- Day’s Range
- $288.20 - $307.19
- 52-Week Range
- $181.00 - $437.41
- Previous Close
- $289.50
- Volume
- N/A
- Average Volume (3M)
- 1.96M
- Market Cap
- $42.04B
- Enterprise Value
- $58.69B
- Total Cash (Recent Filing)
- $1.10B
- Total Debt (Recent Filing)
- $238.84M
- Price to Earnings (P/E)
- ―
- Beta
- 1.09
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- -0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth
The higher revenue outlook, supported by continued volume growth and steady ASPs, indicates broadening clinical adoption and stronger commercial execution. Sustained growth across oncology, women’s health, and organ health can expand operating leverage and reinforce Natera’s market position over the next several quarters.
Improving Margins And Cash Generation
Positive operating cash flow and materially higher gross margins show that scale is improving Natera’s underlying economics. Although profitability is not yet established, sustained cash generation provides resources to fund trials, commercial expansion, and technology investment without relying solely on external capital.
MRD Adoption And Clinical Validation
Rapid MRD volume growth, repeat testing, and expanding clinical evidence support Signatera’s potential as a durable monitoring platform rather than a single-use test. Greater physician confidence and adoption across indications can strengthen recurring utilization, reimbursement discussions, and long-term pricing power.
Bears Say
Profitability Remains Negative
Natera has not yet converted strong revenue growth and improved gross margins into sustainable operating profitability. Continued losses leave execution dependent on maintaining high growth and disciplined spending, while any slowdown could delay the point at which the business consistently funds expansion from earnings.
Elevated Investment And Expense Growth
Higher spending on MRD trials, early detection, pharma services, data initiatives, and commercial programs may support future growth but increases the near-term burden on earnings and cash conversion. If these investments take longer to monetize, margin expansion and the path to profitability could be delayed.
Reimbursement Execution Uncertainty
Broader reimbursement is important to converting clinical evidence into durable test volume and collections. Uncertain MolDX decisions could delay coverage expansion, constrain adoption in additional indications, and make revenue timing less predictable while Natera continues funding evidence generation and regulatory work.
NTRA FAQ
What was Natera’s price range in the past 12 months?
What is Natera’s market cap?
When is Natera’s upcoming earnings report date?
How were Natera’s earnings last quarter?
Is Natera overvalued?
Does Natera pay dividends?
What is Natera’s EPS estimate?
How many shares outstanding does Natera have?
What happened to Natera’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Natera?
What is the TipRanks Smart Score and how is it calculated?
Natera Stock Smart Score
Company Description
Natera
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Solomon Moshkevich
- Employees
- 6,138
- Website
- www.natera.com
- Address
- 13011 McCallen Pass Building A, Austin, TX, 78753, US
Natera (NTRA) Earnings & Revenues
NTRA Company Deck
NTRA Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Natera reported record testing volumes, more than 40% revenue growth excluding true-ups, accelerating MRD adoption, improving underlying gross margins, cash generation, narrowed losses, new Medicare coverage, progress toward a Japan launch, strong clinical evidence, and raised full-year guidance. The main challenges were higher planned operating expenses, near-term COGS pressure from newer products, uncertain timing for additional reimbursement decisions, and significant investment in early cancer detection before it generates revenue. These challenges were presented alongside substantial growth momentum and a long-term plan to reach $6 billion in revenue.
View all NTRA earnings summariesNTRA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 2 | 13 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 1 | 0 | 11 |













